Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc(RARE)股票分析

$16.020

+1.009 (+6.30%)收盘时

Loading chart…
最高
16.270
开盘
15.010
成交量加权均价
15.76
成交量
3.55M
市值
—
最低
14.990
成交额
55.90M
企业价值/息税折旧摊销前利润(TTM)
-8.18

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.

AI 分析 of Ultragenyx Pharmaceutical Inc (RARE)

持有

Ultragenyx Pharmaceutical Inc (RARE) is currently trading at $14.54, with a significant upside potential as analysts have raised price targets to as high as $39, suggesting a potential upside of 166% from current levels. However, the stock has a low RSI of 37.885, indicating it may be oversold, and it has experienced a substantial year-to-date decline of 38.39%. The recent sale of a Priority Review Voucher for $210 million is a positive catalyst, providing non-dilutive capital to support its drug development pipeline. The main risk remains its negative net income, which was -92 million in the latest quarter, indicating ongoing financial challenges. Therefore, while there are positive indicators, the stock's volatility and recent performance suggest a cautious approach, making it a hold for now.

分析师评级(18)

上行空间 +284.83%
买入
10 买入
7 持有
1 卖出
当前: 16.02
最低
35.00
平均
61.65
最高
120.00

Evercore ISI

2026-09-21

目标价

$18

In Line

Barclays

2026-09-21

目标价

$35

增持

Morgan Stanley

2026-09-18

目标价

$20

Equal Weight

Canaccord

2026-09-18

目标价

$39

买入

Cantor Fitzgerald

2026-09-18

目标价

$39

增持

估值指标

Ultragenyx Pharmaceutical Inc(RARE)当前预期市盈率为 0.00,5 年平均预期市盈率为 -7.24。

预期市盈率

严重高估
5 年均值 P/E
-7.24
当前P/E
0.00
高估
-5.12
低估
-9.35

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-7.34
当前EV/EBITDA
-8.18
高估
-4.96
低估
-9.73

预期市销率

低估
5 年均值 P/S
6.74
当前P/S
1.50
高估
10.10
低估
3.38

Alphio AI 对 RARE 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%RARE

$52.29

情景价格

基

基准

基准 · 50%RARE

$49.73

情景价格

悲

悲观

悲观 · 25%RARE

$49.40

情景价格

持有 RARE 的大户

S

Sofinnova Investments, Inc.

+ 持有RARE

+10.25%

3个月收益率

B

Bellevue Asset Management AG

+ 持有RARE

+0.71%

3个月收益率

P

Pale Fire Capital SE

+ 持有RARE

+0.03%

3个月收益率

B

Bluebox Asset Management Uk Ltd.

+ 持有RARE

-0.97%

3个月收益率

B

BIT Capital GmbH

+ 持有RARE

-2.21%

3个月收益率

R

RTW Investments, LP

+ 持有RARE

-8.38%

3个月收益率

RARE 常见问题 —— 由 Alphio AI 解答

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ultragenyx Pharmaceutical Inc (RARE) is currently trading at $14.54, with a significant upside potential as analysts have raised price targets to as high as $39, suggesting a potential upside of 166% from current levels. However, the stock has a low RSI of 37.885, indicating it may be oversold, and it has experienced a substantial year-to-date decline of 38.39%. The recent sale of a Priority Review Voucher for $210 million is a positive catalyst, providing non-dilutive capital to support its drug development pipeline. The main risk remains its negative net income, which was -92 million in the latest quarter, indicating ongoing financial challenges. Therefore, while there are positive indicators, the stock's volatility and recent performance suggest a cautious approach, making it a hold for now.

18 analysts cover RARE: 10 rate it Buy, 7 Hold and 1 Sell. The average price target is 61.65.

humblemarten2026/9/28

Most traders are looking for the next coin that will pump. I'm looking for something else. WHO IS BUYING THE DIPS? Because a green candle tells you what already happened. The reaction after the candle tells you whether the move has real strength. Look at the market right now: BTC is still the liquidity anchor. ETH is trying to regain momentum. SOL and XRP are fighting for attention. ZEC is showing extreme volatility. And names like QNT and HBAR have already shown what happens when liquidity suddenly rotates into a narrative. But here's where traders get trapped: A coin pumps 20–30%. Everyone notices. Everyone starts talking about it. Then late buyers enter. And the original buyers start taking profit. That is how a bullish chart can turn into a brutal trap. ━━━━━━━━━━━━━━ 🧠 HERE'S THE TEST I USE I don't care how big the breakout candle is. I want to see what happens NEXT. Breakout → pullback → buyers defend → higher low → continuation. That is a much healthier structure. But: Breakout → instant FOMO → volume disappears → support breaks. That's distribution risk. Same green candle. Completely different market structure. ━━━━━━━━━━━━━━ ₿ AND THIS IS WHY BTC MATTERS If BTC holds its major support while an altcoin is building higher lows, I'm interested. If BTC starts losing structure while an altcoin is already massively extended, I'm much more careful. Because when liquidity leaves the market: BTC usually reacts first. High-beta alts can react MUCH harder. That's where leverage becomes dangerous. ━━━━━━━━━━━━━━ 🔥 MY CURRENT WATCHLIST BTC — market direction ETH — relative strength SOL — high-beta momentum XRP — large-cap rotation ZEC — extreme volatility QNT / HBAR — momentum after major expansion But I'm NOT chasing the biggest green candle. I'm waiting for the market to prove that buyers are willing to defend the move. ━━━━━━━━━━━━━━ THE HARDEST SKILL IN TRADING ISN'T FINDING A COIN. IT'S KNOWING WHEN NOT TO CHASE IT. You don't need to catch every pump. You need to survive long enough to catch the setups that actually matter. ━━━━━━━━━━━━━━ 👇 ONE QUESTION: If you could trade ONLY ONE for the next 7 days: BTC ETH SOL XRP ZEC QNT HBAR Which one are you choosing — and WHY? Don't just drop the ticker. Give me your reason. I'll reply with the key level I'd be watching. $QNT $RARE $BTC

展开
humblemarten2026/9/27

⚡ FUTURES MARKET ROTATION: TWO SIDES OF THE SAME MOVE QNT • SOON • ARX • BTW • GRASS | PHA • RARE • BR • Q • KMNO September 27, 2026 The latest Futures screen shows a sharp split in market momentum: some contracts are attracting aggressive upside participation, while others are experiencing rapid downside pressure. 🟢 FUTURES GAINERS QNTUSDT — +54.98% SOONUSDT — +35.30% ARXUSDT — +25.83% BTWUSDT — +20.83% GRASSUSDT — +19.69% QNT is clearly leading this snapshot, while SOON and ARX are also showing strong short-term expansion. When several contracts move together, it can indicate concentrated momentum rather than a broad market-wide trend. But strong percentage moves also deserve context. Fast expansion can bring higher volatility, wider intraday swings and rapid reversals, especially in leveraged markets. 🔴 FUTURES LOSERS PHAUSDT — -18.26% RAREUSDT — -15.24% BRUSDT — -13.58% QUSDT — -13.24% KMNOUSDT — -12.86% The downside list tells a different story. PHA is showing the largest decline in this snapshot, followed by RARE and BR. Q and KMNO are also under noticeable short-term pressure. 🧠 WHAT THIS ACTUALLY TELLS US The interesting part isn't simply which token is green or red. It's the speed of the rotation. When futures contracts experience large moves on both sides at the same time, traders should pay attention to: • Momentum persistence vs. sudden reversal • Volume confirmation • Open interest changes • Funding conditions • Liquidation activity • Whether spot markets confirm the futures move A large percentage change alone doesn't explain the underlying market structure. 📌 Key takeaway: This is a snapshot of short-term futures momentum, not a confirmation of a longer-term trend. The strongest-looking move can also become the most volatile one. ⚠️ Risk Disclaimer: This post is for educational and informational purposes only. Futures and leverage involve substantial risk, and rapid price movements can result in significant losses. Always conduct your own research and manage risk carefully. $BTC $RARE $SOONNEW

展开
wolf_gust2026/9/27

$RARE 🔻 RARE — Bearish Setup Current Price: 0.019 Entry: 0.0190–0.0192 TP1: 0.0183 TP2: 0.0176 TP3: 0.0168 SL: 0.0198 Confirmation: A clean break below 0.0188 would strengthen the downside setup.

展开
alpha_baker2026/9/27

$QNT $SOON $RARE 📌 FOMC isn’t just about the rate decision. Traders also watch Fed guidance, market expectations, and BTC’s reaction. Sometimes the biggest move comes from the gap between what was expected and what actually happened. 📊

展开
注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易